Skip header and navigation

2 records – page 1 of 1.

Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by kidney disease. It happens when your kidneys can’t filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medicine used to lower the level of parathyroid hormone in your blood. This will help to balance your calcium and phosphorous levels. Sensipar® is a brand name for cinacalcet. How to take this medicine and what side effects to watch for are reviewed.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1465
Less detail

Dalteparin (Fragmin) to prevent clotting during hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams35807
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1760
Available Online
View Pamphlet
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Dalteparin
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Blood--coagulation
Specialty
Nephrology
Abstract
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1760
Less detail